The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.
复制标题
DOI：
10.1186/s12880-016-0158-4
复制
发表时间：
2016-10-05
影响因子：
2.7
通讯作者：
Bakshi R
中科院分区：
文献类型：
--
作者：
Dupuy SL;Khalid F;Healy BC;Bakshi S;Neema M;Tauhid S;Bakshi R
脊髓萎缩发生在多发性硬化症(MS)的早期，并影响残疾。干扰素β-1a(β-1a)对复发缓解型多发性硬化(RR)患者脊髓萎缩的治疗作用尚未见报道。我们回顾了16例患者连续2年每周肌肉注射干扰素β-1a[基线年龄(平均 ± SD)47.7 ± 7.5年，扩展残疾状态量表评分中位数(范围)1.5(0-2.5)，步行时间4.6 ± 0.7秒；治疗时间68.3 ± 59.9个月]和11名性别和年龄匹配的正常对照(NC)。分别于基线、1年和2年后行3T MRI脊髓成像。用主动表面法测量脊髓体积，计算归一化脊髓面积(SCA)。SCA在MS组和NC组两年内无变化[平均年化差异(95%CI)MS：−0.604×mm2(−1.352，0.144)，p = 0.106；NC：−0.360×mm~2(−1.576，0.855)，p = 0.524]。两组之间的分析表明，研究中SCA的变化没有差异[MS与NC；第一年与基线，平均年化差异(95%CI)0.400平方毫米(−3.350，2.549)，p = 0.780；第二年与第一年：−1.196平方毫米(−0.875，3.266)，p = 0.245；第二年与基线−0.243平方毫米(−1.120，1.607)，p = 0.712]。已经确定的干扰素β-1a治疗与持续的脊髓萎缩无关，或者在2年内，与正常对照组相比，RRMS患者的脊髓体积变化率没有任何差异。这些结果可能反映了一种治疗效果。然而，由于样本量和研究设计，这些结果应该被认为是初步的，并等待确认。
Spinal cord atrophy occurs early in multiple sclerosis (MS) and impacts disability. The therapeutic effect of interferon beta-1a (IFNβ-1a) on spinal cord atrophy in patients with relapsing-remitting (RR) MS has not been explored. We retrospectively identified 16 consecutive patients receiving weekly intramuscular IFNβ-1a for 2 years [baseline age (mean ± SD) 47.7 ± 7.5 years, Expanded Disability Status Scale score median (range) 1.5 (0–2.5), timed 25-foot walk 4.6 ± 0.7 seconds; time on treatment 68.3 ± 59.9 months] and 11 sex- and age-matched normal controls (NC). The spinal cord was imaged at baseline, 1 and 2 years later with 3T MRI. C1-C5 spinal cord volume was measured by an active surface method, from which normalized spinal cord area (SCA) was calculated. SCA showed no change in the MS or NC group over 2 years [mean annualized difference (95 % CI) MS: −0.604 mm2 (−1.352, 0.144), p = 0.106; NC: −0.360 mm2 (−1.576, 0.855), p = 0.524]. Between group analysis indicated no differences in on-study SCA change [MS vs. NC; year 1 vs. baseline, mean annualized difference (95 % CI) 0.400 mm2 (−3.350, 2.549), p = 0.780; year 2 vs. year 1: −1.196 mm2 (−0.875, 3.266), p = 0.245; year 2 vs. baseline −0.243 mm2 (−1.120, 1.607), p = 0.712]. Established IFNβ-1a therapy was not associated with ongoing spinal cord atrophy or any difference in the rate of spinal cord volume change in RRMS compared to NC over 2 years. These results may reflect a treatment effect. However, due to sample size and study design, these results should be considered preliminary and await confirmation.
登录
查看更多内容
影响因子：
2.4
作者：
Healy, Brian C.;Arora, Ashish;Bakshi, Rohit
通讯作者：
Bakshi, Rohit
影响因子：
2.4
作者：
Lin, X;Tench, CR;Constantinescu, CS
通讯作者：
Constantinescu, CS
影响因子：
4
作者：
Kearney, H.;Miszkiel, K. A.;Miller, D. H.
通讯作者：
Miller, D. H.
影响因子：
5.7
作者：
Horsfield MA;Sala S;Neema M;Absinta M;Bakshi A;Sormani MP;Rocca MA;Bakshi R;Filippi M
通讯作者：
Filippi M
DOI：
10.1111/jon.12097
发表时间：
2014-11
期刊：
Journal of neuroimaging : official journal of the American Society of Neuroimaging
影响因子：
--
作者：
Oh J;Seigo M;Saidha S;Sotirchos E;Zackowski K;Chen M;Prince J;Diener-West M;Calabresi PA;Reich DS
通讯作者：
Reich DS